Is Health Politics Different

The aging of the global population, combined with changes in technology and cultural understandings of disease and the body, have thrust discussion and contestation over health into the center of local, national, and global politics. Is the politics of health different from the politics of other policy domains? On a number of dimensions, I conclude that it is. Voters and politicians in the developed world appear more likely to accept redistributive claims with respect to health than they are in other policy areas. Nations vary less widely in spending on health than on other functions of government and policy. Moral claims made about health are more likely to attach to its politics than are moral claims about the environment, labor, finance, and energy. More than these other realms, health politics encompasses issues regarding identity, the human body, and other personal matters that endow the health arena with greater significance. Bureaucratic agencies of state are more involved in the provision and regu...

[1]  D. Blumenthal,et al.  The Heart of Power: Health and Politics in the Oval Office , 2009 .

[2]  M. Schlesinger,et al.  Voices unheard: barriers to expressing dissatisfaction to health plans. , 2002, The Milbank quarterly.

[3]  David J. Rothman,et al.  Strangers At The Bedside: A History Of How Law And Bioethics Transformed Medical Decision Making , 1992 .

[4]  S. Parthasarathy.  Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Health Care , 2007 .

[5]  William E. Patrick.  The Food and Drug Administration , 1988 .

[6]  A. Abbott.  The System of Professions: An Essay on the Division of Expert Labor , 1988 .

[7]  C. F. Chapin.  The American Medical Association, Health Insurance Association of America, and Creation of the Corporate Health Care System , 2010, Studies in American Political Development.

[8]  Susan L. Moffitt.  Promoting Agency Reputation through Public Advice: Advisory Committee Use in the FDA , 2010, The Journal of Politics.

[9]  A. Kleinman.  Catastrophe and caregiving: the failure of medicine as an art , 2008, The Lancet.

[10]  A. Daemmrich.  Pharmacopolitics: Drug Regulation in the United States and Germany , 2004 .

[11]  T. Cook,et al.  Epidemics and agendas: the politics of nightly news coverage of AIDS. , 1991, Journal of health politics, policy and law.

[12]  Alan V. Deardorff,et al.  Lobbying as Legislative Subsidy , 2006, American Political Science Review.

[13]  Kimberly J Morgan,et al.  The Delegated Welfare State: Medicare, Markets, and the Governance of Social Policy , 2011 .

[14]  M. Gusmano,et al.  Healthy Voices, Unhealthy Silence: Advocacy and Health Policy for the Poor , 2007 .

[15]  J. Clapp,et al.  Development as freedom , 1999 .

[16]  S. Steinmo,et al.  It's the institutions, stupid! Why comprehensive national health insurance always fails in America. , 1995, Journal of health politics, policy and law.

[17]  T. Skocpol,et al.  Protecting soldiers and mothers : the political origins of social policy in the United States , 1993 .

[18]  S. Dewan,et al.  Comparing Public Spending and Priorities Across OECD Countries. , 2009 .

[19]  L. Jacobs.  Politics of America's supply state: health reform and technology. , 1995, Health Affairs.

[20]  H. Marks,et al.  Reviews: Medicine and Health-The Progress of Experiment: Science and Therapeutic Reform in the United States, 1900-1990 , 1997 .

[21]  David Brain.  Professional Powers: A Study of the Institutionalization of Formal Knowledge.By Eliot Freidson. University of Chicago Press. 241 pp. $20.00 , 1988 .

[22]  Jacob S. Hacker.  The divided welfare state: The bat-tle over public and private social benefits in the United States , 2002 .

[23]  G. Torrance,et al.  The utility of different health states as perceived by the general public. , 1978, Journal of chronic diseases.

[24]  Michael M. Ting,et al.  REGULATORY ERRORS WITH ENDOGENOUS AGENDAS , 2007 .

[25]  E. Immergut.  Health Politics: Interests and Institutions in Western Europe , 1992 .

[26]  Politics and Funding in the U.S. Public Biomedical R&D System , 2008, Science.

[27]  J. Hacker.  Privatizing Risk without Privatizing the Welfare State: The Hidden Politics of Social Policy Retrenchment in the United States , 2004, American Political Science Review.

[28]  V. Shavers,et al.  Racial and ethnic disparities in the receipt of cancer treatment. , 2002, Journal of the National Cancer Institute.

[29]  Jacob S. Hacker,et al.  The Historical Logic of National Health Insurance: Structure and Sequence in the Development of British, Canadian, and U.S. Medical Policy , 1998, Studies in American Political Development.

[30]  Cathy Cohen.  The Boundaries of Blackness: AIDS and the Breakdown of Black Politics , 1999 .

[31]  Tom Baker.  The Medical Malpractice Myth , 2005 .

[32]  E. Armstrong,et al.  Whose deaths matter? Mortality, advocacy, and attention to disease in the mass media. , 2006, Journal of health politics, policy and law.

[33]  E. M. Fonseca.  Reforming pharmaceutical regulation : a case study of generic drugs in Brazil , 2014 .

[34]  E. Hurley.  Prescribing by numbers , 2000 .

[35]  Daniel Carpenter,et al.  Groups, the Media, Agency Waiting Costs, and FDA Drug Approval , 2002 .

[36]  M. Rodwin.  Conflicts of Interest and the Future of Medicine , 2011 .

[37]  Norman Daniels,et al.  Justice, Health, and Healthcare , 2001, The American journal of bioethics : AJOB.

[38]  J. Oberlander.  The Political Life of Medicare , 2003 .

[39]  W. Encinosa,et al.  Technology in American Health Care: Policy Directions for Effective Evaluation and Management , 2004 .

[40]  L. Jacobs.  The Medicare approach: political choice and American institutions. , 2007, Journal of health politics, policy and law.

[41]  V. Rodwin,et al.  Health care under French national health insurance. , 1993, Health affairs.

[42]  Steven G. Epstein,et al.  Inclusion: The Politics of Difference in Medical Research , 2007 .

[43]  Paul Starr.  The social transformation of American medicine , 1983 .

[44]  C. Volden,et al.  States as Policy Laboratories: Emulating Success in the Children's Health Insurance Program , 2006 .

[45]  John D. Huber,et al.  Legislatures and statutory control of bureaucracy , 2001 .

[46]  Daniel Carpenter,et al.  Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA , 2014 .

[47]  M. Nussbaum.  Creating Capabilities: The Human Development Approach , 2011 .

[48]  M. Schlesinger.  A loss of faith: the sources of reduced political legitimacy for the American medical profession. , 2002, The Milbank quarterly.

[49]  D. Carpenter.  Protection without Capture: Product Approval by a Politically Responsive, Learning Regulator , 2004, American Political Science Review.

[50]  Moshe Maor,et al.  Organizational Reputations and the Observability of Public Warnings in 10 Pharmaceutical Markets , 2011 .

[51]  S. Jasanoff,et al.  The Fifth Branch: Science Advisers as Policymakers. , 1991 .

[52]  D. Fox,et al.  The Convergence of Science and Governance , 2010 .

[53]  Martha Derthick.  Up In Smoke: From Legislation To Litigation In Tobacco Politics , 2001 .

[54]  M. Peterson.  It was a different time: Obama and the unique opportunity for health care reform. , 2011, Journal of health politics, policy and law.